# CJC-1295

> GHRH analog often paired with Ipamorelin for pulsatile support.

Source: https://peptides.cafe/peptide/cjc-1295
Category: Growth Hormone Axis
Tag: Growth hormone

## Mechanism
A synthetic analog of growth hormone-releasing hormone (GHRH). The non-DAC version has a short half-life that preserves pulsatile GH release, while DAC variants extend the half-life via albumin binding. Research focuses on stimulating endogenous GH and IGF-1 production via the pituitary.

## Research areas
- Endogenous GH pulse amplitude
- IGF-1 elevation
- Body composition in adult GH-deficient research
- Sleep architecture (slow-wave sleep)

## Common research protocols
- Pulsatile research stack: Combined with Ipamorelin in research to layer GHRH + ghrelin-mimetic signaling for pulsatile GH release.
- DAC variant: Studied as longer-acting GH elevation in clinical pharmacology trials.

## Study summaries
- "Sustained pharmacological GH activity in healthy adults via DAC technology" — Journal of Clinical Endocrinology & Metabolism (2006): Established prolonged GH/IGF-1 elevation from single subcutaneous doses.
- "GHRH analogs and the GH-IGF-1 axis" — Endocrine Reviews (2011): Mechanistic review of GHRH-analog pharmacology.

## Considerations
- GH-axis manipulation may affect glucose tolerance.
- Banned in competitive sport (WADA).
- Requires physician oversight in any therapeutic context.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.